Skip to main content
SpringerLink
Log in

Considerations for Choosing First-Line Urate-Lowering Treatment in Older Patients with Comorbid Conditions

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Gout is the most common inflammatory arthritis in adults. The prevalence of gout increases with age. Urate-lowering treatment (ULT) among older patients is often challenging in that patients frequently suffer insufficient effectiveness or adverse events due to comorbidities, concurrent medications, and altered pharmacokinetics. The large-scale randomized controlled trials (RCTs) directly investigating gout patients regarding cardiovascular (CV) safety have only recently been introduced; CARES and FAST compared the CV safety of the two xanthine oxidase inhibitors (XOis), febuxostat versus allopurinol, in patients with gout. Based on the CARES trial that showed CV concerns with febuxostat, the current international guidelines recommend allopurinol as first-line ULT in gout, while preserving other agents as a second-line treatment, despite a higher potency of febuxostat. XOis would be more suitable than uricosurics to treat older patients with gout due to the high prevalence of chronic kidney disease (CKD) in older patients. However, allopurinol alone might not achieve the target serum uric acid levels below 6 mg/dL and CKD might confer an increased risk of allopurinol induced cutaneous adverse reactions in older patients. Furthermore, as well as the later analysis of CARES participants who were lost to follow-up, data from the FAST trial and real-world studies suggest non-inferior CV safety for febuxostat compared to allopurinol even in the presence of CV diseases. Thus, febuxostat use in older patients with renal impairment may be more positively considered. The combination therapy of a novel uricosuric, verinurad, plus febuxostat reduced albuminuria in hyperuricemic patients with type 2 diabetes and CKD in a phase 2a trial, and further RCTs are awaited. Finally, the sodium-glucose cotransporter-2 inhibitor class of oral hypoglycemic agents, known to exert beneficial CV and renal effects independent of glycemic control, have shown a uricosuric effect and could be used as adjunctive therapy in older patients with cardiorenal comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811–27.

    Article  CAS  Google Scholar 

  2. Kang EH, Kim SC. Cardiovascular safety of urate lowering therapies. Curr Rheumatol Rep. 2019;21(9):48.

    Article  Google Scholar 

  3. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654–61.

    Article  CAS  Google Scholar 

  4. Suissa S, Suissa K, Hudson M. Effectiveness of allopurinol in reducing mortality: time-related biases in observational studies. Arthritis Rheumatol. 2021;73(9):1749–57.

    Article  CAS  Google Scholar 

  5. Suissa S, Suissa K, Hudson M. Allopurinol and cardiovascular events: time-related biases in observational studies. Arthritis Care Res (Hoboken). 2022;74(5):858–65.

    Article  CAS  Google Scholar 

  6. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, CARES Investigators, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.

    Article  CAS  Google Scholar 

  7. Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, FAST Study Group, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–57.

    Article  CAS  Google Scholar 

  8. Fam AG. Gout in the elderly. Clinical presentation and treatment Drugs Aging. 1998;13(3):229–43.

    Article  CAS  Google Scholar 

  9. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;3(12):36.

    Article  Google Scholar 

  10. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 2014;66(1):185–96.

    Article  Google Scholar 

  11. Farquhar H, Vargas-Santos AB, Pisaniello HL, Fisher M, Hill C, Gaffo AL, et al. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol Adv Pract. 2021;5(1):rkaa073.

    Article  Google Scholar 

  12. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.

    Article  CAS  Google Scholar 

  13. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.

    Article  Google Scholar 

  14. Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633–41.

    Article  Google Scholar 

  15. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–36.

    Article  CAS  Google Scholar 

  16. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.

    Article  CAS  Google Scholar 

  17. Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, Taiwan Allopurinol-SCAR Consortium, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.

    Article  Google Scholar 

  18. Dean L, Kane M. Allopurinol Therapy and HLA-B*58:01 Genotype. 2013 Mar 26 [Updated 2020 Dec 9]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. https://www.ncbi.nlm.nih.gov/books/NBK127547/. Accessed 20 June 2022.

  19. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–8.

    Article  CAS  Google Scholar 

  20. Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Curr Opin Rheumatol. 2014;26(2):169–75.

    Article  CAS  Google Scholar 

  21. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892–7.

    Article  CAS  Google Scholar 

  22. Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51–6.

    Article  CAS  Google Scholar 

  23. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31:643–65.

    Article  CAS  Google Scholar 

  24. Sato T, Cheng CL, Park HW, Kao Yang YH, Yang MS, Fujita M, et al. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: a population-based cohort study. Clin Transl Sci. 2021;14(3):1002–14.

    Article  CAS  Google Scholar 

  25. Kang EH, Park EH, Shin A, Song JS, Kim SC. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J. 2021;42(44):4578–88.

    Article  CAS  Google Scholar 

  26. Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang M, et al. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71(9):994–1004.

    Article  CAS  Google Scholar 

  27. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207988Orig1s000CrossR.pdf. Accessed 20 Dec 2021.

  28. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf. Accessed 20 Dec 2021.

  29. https://www.ema.europa.eu/en/documents/rmp-summary/zurampic-epar-risk-management-plan-summary_en.pdf. Accessed 20 Dec 2021.

  30. Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, SAPPHIRE investigators, et al. Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant. 2022;37(8):1461–71.

    Article  Google Scholar 

  31. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32.

    Article  CAS  Google Scholar 

  32. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–56.

    Article  CAS  Google Scholar 

  33. McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12(5):807–16.

    Article  Google Scholar 

  34. Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, et al. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 2021;73(8):1514–22.

    Article  CAS  Google Scholar 

  35. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, OPT-CHF Investigators, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–9.

    Article  CAS  Google Scholar 

  36. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, NHLBI Heart Failure Clinical Research Network, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–71.

    Article  CAS  Google Scholar 

  37. Sakuma M, Toyoda S, Arikawa T, Koyabu Y, Kato T, Adachi T, et al. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial. PLoS ONE. 2022;17(1): e0261445.

    Article  CAS  Google Scholar 

  38. Yokota T, Fukushima A, Kinugawa S, Okumura T, Murohara T, Tsutsui H. Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF). Int Heart J. 2018;59(5):976–82.

    Article  CAS  Google Scholar 

  39. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–7.

    Article  CAS  Google Scholar 

  40. Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284–93.

    Article  CAS  Google Scholar 

  41. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, et al. Febuxostat for cerebral and CaRdiorenovascular events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778–86.

    Article  CAS  Google Scholar 

  42. Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H, PRIZE study investigators, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Med. 2020;17(4):e1003095.

    Article  Google Scholar 

  43. Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, et al. Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST)—protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J. 2018;3(3):281–90.

    Article  Google Scholar 

  44. Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, ALL-HEART study group, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016;6(9):e013774.

    Article  Google Scholar 

  45. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New Perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol. 2018;70(11):1702–9.

    Article  Google Scholar 

  46. O’Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022;1(3):10.

    Google Scholar 

  47. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation. 2018;138(11):1116–26.

    Article  Google Scholar 

  48. Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 2019;58(12):2122–9.

    Article  CAS  Google Scholar 

  49. Pawar A, Desai RJ, Liu J, Kim E, Kim SC. Updated assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. J Am Heart Assoc. 2021;10(7): e020045.

    Article  Google Scholar 

  50. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, FEATHER Study Investigators, et al. Febuxostat therapy for patients with stage 3 CKD and ASYMPTOMATIC HYPERURICEMIA: A RANDOMIZED TRIAL. Am J Kidney Dis. 2018;72(6):798–810.

    Article  CAS  Google Scholar 

  51. Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, PERL Study Group, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–503.

    Article  CAS  Google Scholar 

  52. Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, CKD-FIX Study Investigators, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–13.

    Article  CAS  Google Scholar 

  53. Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97–111.

    Article  Google Scholar 

  54. Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601.

    Article  Google Scholar 

  55. Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study). Arthritis Rheumatol. 2017;69(1):203–12.

    Article  CAS  Google Scholar 

  56. Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76(5):811–20.

    Article  CAS  Google Scholar 

  57. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019;21(1):8.

    Article  Google Scholar 

  58. Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnsson E, Erlandsson F, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021;77(4):481–9.

    Article  CAS  Google Scholar 

  59. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.

    Article  CAS  Google Scholar 

  60. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522–8.

    Article  CAS  Google Scholar 

  61. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72:879–95.

    Article  Google Scholar 

  62. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89.

    Article  CAS  Google Scholar 

  63. Čertíková Chábová V, Zakiyanov O. Sodium glucose cotransporter-2 inhibitors: spotlight on favorable effects on clinical outcomes beyond diabetes. Int J Mol Sci. 2022;23(5):2812.

    Article  Google Scholar 

  64. Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. 2021;144(1):74–84.

    Article  CAS  Google Scholar 

  65. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, ESC Scientific Document Group, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.

    Article  Google Scholar 

  66. Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, et al. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. Eur J Heart Fail. 2020;22(11):1984–6.

    Article  Google Scholar 

  67. Yip ASY, Leong S, Teo YH, Teo YN, Syn NLX, See RM, et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Ther Adv Chronic Dis. 2022;13:20406223221083508.

    Article  Google Scholar 

  68. Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186–94.

    Article  Google Scholar 

  69. Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Wu MJ, et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open. 2021;4(11): e2135353.

    Article  Google Scholar 

  70. Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021;12(3):463–73.

    Article  Google Scholar 

  71. Yu H, Liu X, Song Y, Cheng J, Bao H, Qin L, et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol. 2018;22(6):1324–30.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, 166 Gumiro Bundang-gu, Seongnam-si, Kyeongki-do, South Korea

    Eun Ha Kang

  2. Seoul National University College of Medicine, Seoul, South Korea

    Eun Ha Kang

Authors
  1. Eun Ha Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eun Ha Kang.

Ethics declarations

Funding

None.

Competing interests

No financial or non-financial interests exist that are directly or indirectly related to this work.

Ethics approval

There was no need to obtain ethics approval for a review article according to the Institutional Review Board of Seoul National University Bundang Hospital.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Code availability

Not applicable.

Author contributions

Eun Ha Kang drafted, reviewed, and edited the manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, E.H. Considerations for Choosing First-Line Urate-Lowering Treatment in Older Patients with Comorbid Conditions. Drugs Aging 39, 923–933 (2022). https://doi.org/10.1007/s40266-022-00986-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-022-00986-3

Search

Navigation